Art. -Nr.: HY-Y1718

Tridecanoic acid

(Synonyms: N-Tridecanoic acid)

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Tridecanoic acid (N-Tridecanoic acid) is a medium-chain saturated fatty acid and inhibitor with no antibacterial activity against enterohemorrhagic E. coli (EHEC). When used in combination with Ciprofloxacin (HY-B0356) or Ampicillin (HY-B0522), Tridecanoic acid suppresses persister formation in exponentially growing E. coli and EHEC, but exerts no inhibitory effect on persister formation induced by Kanamycin (HY-16566) or in stationary-phase cells. Tridecanoic acid inhibits biofilm formation in EHEC. It can be used in the research of bacterial infections.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.0%
CAS. Nr.: 638-53-9
Formel: C₁₃H₂₆O₂
Molecular Weight:214.34

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Tridecanoic acid Chemical Structure

CAS. Nr.: 638-53-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- Clinical Trial
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	2.5 x 10² μM Compound: TA	Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 37462318]
Caco-2	IC₅₀	2.8 x 10² μM Compound: TA	Cytotoxicity against human Caco-2 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Cytotoxicity against human Caco-2 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 37462318]
CHO	EC₅₀	1.7 μM Compound: 19	Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as beta-arrestin 2 recruitment measured after 90 mins by beta-galactosidase based PathHunter assay Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as beta-arrestin 2 recruitment measured after 90 mins by beta-galactosidase based PathHunter assay	[PMID: 31721581]
CHO	EC₅₀	9.61 μM Compound: 19	Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as inhibition of forskolin-stimulated [3H]cAMP accumulation preincubated for 5 mins followed by forskolin stimulation and measured after 15 m Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as inhibition of forskolin-stimulated [3H]cAMP accumulation preincubated for 5 mins followed by forskolin stimulation and measured after 15 m	[PMID: 31721581]

In Vitro

Tridecanoic acid (1 mM; 3-72 h), when used in combination with Ciprofloxacin (HY-B0356), reduces the persister formation capacity of exponentially growing Escherichia coli BW25113 by 44-fold; when the incubation time is extended to 72 h, persisters are almost completely inactivated^[1].
When used in combination with Ciprofloxacin, tridecanoic acid (1 mM; 3-72 h) reduces the formation of persister cells of exponentially growing enterohemorrhagic Escherichia coli EDL933 by 9-fold, and almost complete cell inactivation occurs after extended incubation for 72 h^[1].
Combination treatment with Tridecanoic acid (1 mM; 6 h) and Ampicillin (HY-B0522) reduces the persister formation of enterohemorrhagic E. coli EDL933 by 10-fold^[1].
Tridecanoic acid (1 mM; 18 h) exhibits no antibacterial activity against enterohemorrhagic Escherichia coli EDL933 during 18 h of incubation, and slightly promotes its growth in the exponential growth phase and early stationary phase^[1].
Tridecanoic acid (1 mM; 24 h) inhibits biofilm formation by enterohaemorrhagic Escherichia coli EDL933 without exerting direct antibacterial activity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 638-53-9
Appearance Solid
Molecular Weight 214.34
Formel C₁₃H₂₆O₂
Color White to off-white
SMILES

CCCCCCCCCCCCC(O)=O
Synonyms

N-Tridecanoic acid
Structure Classification
- Ketones, Aldehydes, Acids
Initial Source
- Endogenous metabolite
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

Nature

Lithocholic acid phenocopies anti-ageing effects of calorie restriction. [Abstract]

2025 Jul;643(8070):192-200. PMID: 39695227

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (466.55 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.6655 mL

23.3274 mL

46.6548 mL

5 mM

0.9331 mL

4.6655 mL

9.3310 mL

10 mM

0.4665 mL

2.3327 mL

4.6655 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 6.25 mg/mL (29.16 mM); Clear solution

This protocol yields a clear solution of ≥ 6.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (62.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 6.25 mg/mL (29.16 mM); Clear solution

This protocol yields a clear solution of ≥ 6.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (62.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 6.25 mg/mL (29.16 mM); Clear solution

This protocol yields a clear solution of ≥ 6.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (62.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (267 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Jin X, et al. Undecanoic acid, lauric acid, and N-tridecanoic acid inhibit Escherichia coli persistence and biofilm formation[J]. Journal of microbiology and biotechnology, 2020, 31(1): 130.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.6655 mL	23.3274 mL	46.6548 mL	116.6371 mL
	5 mM	0.9331 mL	4.6655 mL	9.3310 mL	23.3274 mL
	10 mM	0.4665 mL	2.3327 mL	4.6655 mL	11.6637 mL
	15 mM	0.3110 mL	1.5552 mL	3.1103 mL	7.7758 mL
	20 mM	0.2333 mL	1.1664 mL	2.3327 mL	5.8319 mL
	25 mM	0.1866 mL	0.9331 mL	1.8662 mL	4.6655 mL
	30 mM	0.1555 mL	0.7776 mL	1.5552 mL	3.8879 mL
	40 mM	0.1166 mL	0.5832 mL	1.1664 mL	2.9159 mL
	50 mM	0.0933 mL	0.4665 mL	0.9331 mL	2.3327 mL
	60 mM	0.0778 mL	0.3888 mL	0.7776 mL	1.9440 mL
	80 mM	0.0583 mL	0.2916 mL	0.5832 mL	1.4580 mL
	100 mM	0.0467 mL	0.2333 mL	0.4665 mL	1.1664 mL

Keywords

Tridecanoic acid

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Tridecanoic acid

Anti-Infection Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Clinical Compound Library

Drug Repurposing Compound Library

Lipid Compound Library

Antibacterial Compound Library

Medicine Food Homology Compound Library

Traditional Chinese Medicine Active Compound Library

Food Additive Library

Food-Sourced Compound Library

Human Metabolite Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Fatty Acids Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Mouse Metabolite Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Flavors and Fragrances Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Tridecanoic acid

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Tridecanoic acid Related Classifications

HY-Y1718 Related Classifications